



**QUEEN'S
UNIVERSITY
BELFAST**

Rapid quantification of microRNAs in plasma using a fast real time PCR system

Andrews, W. J., Brown, E. D., Dellett, M., Hogg, R. E., & Simpson, D. A. (2015). Rapid quantification of microRNAs in plasma using a fast real time PCR system. *BioTechniques*, 58(5), 244-252.
<http://www.biotechniques.com/BiotechniquesJournal/2015/May/Rapid-quantification-of-microRNAs-in-plasma-using-a-fast-real-time-PCR-system/biotechniques-358345.html>

Published in:
BioTechniques

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights
© 2015 The Authors

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

1 **Title Page**

2

3 **Rapid quantification of microRNAs in plasma using a fast real time PCR system**

4 William John Andrews, Eoin Daniel Brown, Margaret Dellett, Ruth Esther Hogg, David Arthur
5 Simpson*

6 Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, United
7 Kingdom

8

9 Address correspondence to David Arthur Simpson*: Centre for Experimental Medicine, Queen's
10 University Belfast, Institute of Clinical Science – Block A, Royal Victoria Hospital, Grosvenor Road,
11 Belfast, BT12 6BA, Northern Ireland, United Kingdom. E-mail: David.Simpson@qub.ac.uk

12

13

14 **Keywords:** PCR; microRNA; RT-PCR; biomarker

15

16 **Abstract word count:** 199

17 **Manuscript word count (Intro, Methods and Results/Discussion):** 2137

18

19

20

21

22 **Abstract**

23 The ability to rapidly detect circulating small RNAs, in particular microRNAs (miRNAs), would
24 further increase their already established potential as biomarkers in a range of conditions. One rate-
25 limiting factor is the time taken to perform quantitative real time PCR amplification. We therefore
26 evaluated the ability of a novel thermal cycler to perform this step in less than 10 minutes.
27 Quantitative PCR was performed on an xpress® thermal cycler (BJS Biotechnologies, **Perivale,**
28 **UK**), which employs a resistive heating system and forced air cooling to achieve thermal ramp rates
29 of 10 °C/s, and a conventional peltier-controlled LightCycler 480 system (Roche, **Basel, Switzerland**)
30 ramping at 4.8 °C/s. The threshold cycle (Ct) for detection of 18S rDNA from a standard genomic
31 DNA sample was **significantly** more variable across the block (**F-test, $p=2.4 \times 10^{-25}$**) for the xpress
32 (20.01±0.47SD) than the LightCycler (19.87±0.04SD). RNA was extracted from human plasma,
33 reverse transcribed and a panel of miRNAs amplified and detected using SYBR green (Kapa
34 Biosystems, **Wilmington, Ma, USA**). The sensitivity of both systems was broadly comparable and
35 both detected a panel of miRNAs reliably and indicated similar relative abundances. The xpress
36 thermal cycler facilitates rapid qPCR detection of small RNAs and brings point-of care diagnostics
37 based upon circulating miRNAs a step closer to reality.

38

39 **Method summary**

40 We describe a quantitative PCR platform which enables faster ramping between temperatures than
41 conventional peltier-based systems, thereby reducing the time required to complete a PCR reaction.
42 This is particularly important for the development of clinical biomarkers for acute conditions and the
43 feasibility of detecting miRNAs in plasma is demonstrated.

44

45

46

47 **Introduction**

48 PCR is ubiquitous throughout the life and medical sciences and a reduction in the time required to
49 complete a PCR reaction would therefore be of immense benefit. **Whilst the choice of fast enzyme is**
50 **important for the optimization of fast PCR-based systems(1), (2), the speed at which the temperature**
51 **of the sample can be altered during thermal cycling is the primary rate-limiting factor (3).** Using
52 prototype systems many investigators have demonstrated that rapid thermal cycling is possible (4),
53 (5), and under extreme conditions can be completed in less than one minute (6)! The predominant
54 format of existing thermal cyclers comprises a 96 or 384 well block, the temperature of which is
55 controlled by a peltier-based system limited to ramp rates of approximately 4 °C/s. Several
56 quantitative PCR systems which employ rapid thermal cycling are available commercially, but these
57 are based on glass capillaries (LightCycler, Roche) (7) or plastic tubes placed in a centrifuge (Rotor-
58 gene, Qiagen, **Crawley, UK**). An alternative rapid plate-based approach, which can be more easily
59 integrated into existing workflows, has now been developed. The xpress® thermal cycler (BJS
60 Biotechnologies) employs resistive heating and forced air cooling to enable ramp rates of up to 10
61 °C/s.

62 One of the main applications of PCR is for the quantitation of RNA targets. Following reverse
63 transcription into cDNA, amplification of targets is detected by incorporation of a double-stranded
64 DNA binding fluorescent dye (principally SYBR green) or use of a sequence-specific probe-based
65 system **e.g. Taqman**. This quantitative reverse transcription PCR (RT-qPCR) approach can be
66 modified to measure small RNAs, specifically miRNAs. Following the discovery that miRNAs exist
67 in a stable form within blood (8)(9)), their potential as biomarkers was soon realised. MiRNA
68 expression patterns characteristic of cancer, cardiovascular disease, diabetes, Alzheimer's and many
69 other conditions have now been reported (10)(11), (12, 12). Typically global miRNA profiles are
70 initially assessed in a discovery cohort using microarrays or deep sequencing and selected informative
71 miRNAs are subsequently measured in a larger population. The method of choice for measuring a
72 defined, diagnostic panel of miRNAs is RT-qPCR.

73 To perform RT-qPCR, RNA must be extracted from plasma or serum, reverse transcribed and target
74 miRNAs amplified in individual PCR reactions. This process takes several hours and is sufficient for
75 the current applications of circulating miRNA biomarkers for which results may be reported within
76 days or weeks. However, a more rapid assay would facilitate point of care diagnostics and expand
77 potential uses. For example, changes in miRNAs have been associated with cardiac disease (10), and
78 the ability to measure them in plasma quickly might provide an earlier biomarker for diagnosis of
79 myocardial infarction and ensure more timely therapeutic intervention (13). We therefore assessed the
80 ability of the xpress system to quantify miRNAs in plasma using high speed cycling in comparison
81 with an existing qPCR system (LightCycler480, Roche).

82 It was possible to amplify RNAs from plasma cDNA in less than 10 minutes using the xpress
83 system, compared with ~40 minutes with the LightCycler. However, although the performance of
84 both systems was broadly comparable, variability across the plate and between replicate samples was
85 greater in the xpress.

86

87 **Materials and Methods**

88 **Oligonucleotide synthesis**

89 All oligonucleotides (Integrated DNA Technologies, Leuven, Belgium) were reconstituted as 100 μ M
90 stocks; DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0), RNA in nuclease free water, and
91 stored at -80 °C. Sequences of the RNA miRNA mimic, Reverse transcription oligo, 18S and miRNA
92 primers are shown in Table 1.

93

94 **qPCR instruments**

95 The xpress system (Figure 1) employs resistive heating and forced air cooling to facilitate rapid
96 changes in temperature. PCR reactions are performed within proprietary 'xxplates' which comprise a

97 metal base fused with plastic wells, meaning that the sample is only 10 μm from the heat source
98 (Figure 1A). To enable thermal uniformity across all the samples to within ± 0.3 $^{\circ}\text{C}$ during holds at a
99 static temperature or within ± 0.8 $^{\circ}\text{C}$ during fast ramping (10 $^{\circ}\text{C}/\text{s}$), the xpress uses an array of
100 infrared sensors to determine the temperature of the test samples and a control algorithm adjusts the
101 heating patterns at a rate of 100 times per second. The xplates to be analysed using the xpress
102 system were prepared as follows. Plates were sealed using xpress compatible polarised sealing strips
103 heated at 170 $^{\circ}\text{C}$ for 1.5 s using the heat sealer provided (Figure 1B). They were then centrifuged at
104 1000 rpm for 1 minute in dedicated holders in the centrifuge provided before loading into the xpress
105 cycling unit (Figure 1B). The LightCycler 480 system with a 384 well block installed has a thermal
106 uniformity of ± 0.4 $^{\circ}\text{C}$ within 60 s of target attainment (72 $^{\circ}\text{C}$). PCR plates (Roche) to be analysed
107 were prepared following the manufacturer's instructions (LightCycler 480 user manual). In brief,
108 plates were sealed using the manufacturer's sealing strips, ensuring all wells were securely covered,
109 followed by centrifugation at 1200 rpm for 2 minutes. Plates were then loaded into the LightCycler.

110

111 **PCR conditions and data analysis**

112 All PCR reactions were performed for 40 cycles with SYBR Fast qPCR Mastermix (final
113 concentration 1X, Kapa Biosystems, 1 μl DNA or cDNA template, 5 μM forward and reverse
114 primers) in a final volume of 5 μl . The cycling conditions used for amplification of 18S rDNA are
115 shown in Table 2 and employed the same ramp rate on both machines (4.8 $^{\circ}\text{C}/\text{s}$). 18S rDNA
116 amplification used 1 μl of genomic DNA as template (2.5 $\text{ng}/\mu\text{l}$) either neat, or serially diluted in PCR
117 grade water. The same conditions were used for detection of miRNAs, but with a reduced
118 annealing/extension temperature of 55 $^{\circ}\text{C}$ and with ramp rates increased to 10 $^{\circ}\text{C}/\text{s}$ on the xpress.
119 Raw fluorescence data were analysed by baseline normalisation and Ct values were called in
120 accordance with the data analysis software provided on each instrument (threshold set using the
121 second derivative maximum algorithm on the LightCycler and manually on the xpress).

122

123 **RNA templates**

124 An RNA oligonucleotide with the sequence of miR-21 and a polyA tail (miRNA mimic) (Table 1)
125 was reverse transcribed using 5 pmol of oligodT-RACE primer; the template was denatured at 50 °C
126 for 5 minutes, then cooled to 4 °C for addition of SuperScript III (Life Technologies, Paisley, UK)
127 followed by incubation at 40 °C for 60 minutes. Total RNA including small RNAs was extracted
128 from 200 µl of human plasma using a miRNeasy Serum/plasma kit according to the manufacturer's
129 protocol (Qiagen, Crawley, UK) and polyadenylated for 1 hour at 37 °C in a 25 µl reaction containing
130 2 U poly(A) polymerase, 2.5mM MgCl₂ and 1mM ATP (Ambion, Life Technologies). A 5 µl volume
131 of polyadenylated RNA was then incubated at 65 °C for 5 minutes with 0.5 µg oligo(dT)-RACE
132 primer and 1µl 10 mM dNTPs in a reaction volume of 8 µl. Following addition of 200 U SuperScript
133 III, 1 U RNaseOut, 1 µl 0.1 M DTT and 4 µl 5X RT buffer, the reaction was incubated at 50 °C for 1
134 hour followed by 70 °C for 15 minutes.

135

136 **Ethics**

137 This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all
138 procedures involving human participants/patients were approved by the Research Ethics Committee
139 of the School of Medicine and Dentistry, Queen's University Belfast (Ref:11/05v3). Written informed
140 consent was obtained from all participants

141

142 **Results and Discussion**

143 To assess consistency across the plate, a single mastermix for amplification of a 155 bp amplicon
144 from 18S rDNA was aliquoted into 48 wells distributed evenly across each type of plate (Suppl.
145 Figure. 1). Amplification was performed using the same cycling conditions on both systems (Table 2).
146 **The mean Ct values were very similar from the xxpress (20.01±0.47SD) and the LightCycler**
147 **(19.87±0.04SD), although the LightCycler was significantly lower (t-test, p = 0.035). However the**

148 xpress exhibited significantly greater variability than the LightCycler, which generated extremely
149 consistent Ct values (F-test, $p=2.4 \times 10^{-25}$) (Figure 2). Although the performance of the xpress was
150 less robust, it could still be used in situations requiring rapid detection of large variations in
151 expression between samples (with the inclusion of appropriate replicates). The spread in Ct values on
152 the xpress was in part linked to the position of the sample on the xxplate, with adjacent wells tending
153 to vary from the mean Ct value in the same direction. The greater variation observed with the xpress
154 may not be due to poorer temperature control across the plate, but could be related to the optical
155 system, which is amenable to improvement in subsequent versions. To compare the sensitivity of the
156 two platforms, highly abundant 18S rDNA was amplified from a dilution series of genomic DNA. The
157 mean Ct values at each template concentration were not significantly different between platforms (t-
158 test, $p>0.05$). In both cases the Ct values were highly correlated with template concentration
159 (LightCycler, $R^2 = 0.9547$; xpress, $R^2 = 0.9878$), although again there was a significantly greater
160 variation in Ct values for replicates in the xpress at several concentrations (Figure 3A).

161 The method described by Shi and Chiang (14)), was then used to detect miRNAs. Total RNA,
162 including miRNAs, is polyadenylated and then reverse-transcribed with a poly(T) adapter into
163 cDNAs. These are subsequently amplified using a miRNA-specific forward primer and a sequence
164 complementary to the poly(T) adapter as the reverse primer. Initially we tested the ability of each
165 platform to detect a miRNA mimic synthesised with a polyA tail already incorporated (thereby
166 removing any variability associated with the polyadenylation reaction). The limit of detection, as
167 estimated from the linear portion of the standard curve, was approximately 1×10^6 RNA template
168 molecules for both systems (Figure 3B). Given the high concentrations of specific template miRNA
169 used in this assay, a better signal may be obtained using cell-derived RNA as template (15)).

170 Our ultimate aim is the rapid detection of miRNAs from blood as biomarkers of cancer and other
171 diseases. As a step towards this we measured the expression of several miRNAs in RNA extracted
172 from three human plasma samples; miR-21, an 'oncomir' which plays a role in many types of cancer
173 (16), (17),(18)and heart disease (19)) and has been reported to be elevated in blood from cancer
174 patients (20), (21), miR-22, which has is also differentially expressed in various types of cancer (22)),

175 miR-126, which is involved in regulation of angiogenesis (23)) and miR-486, which is down-
176 regulated in lung cancer and proposed as a biomarker for detection of lung cancer in plasma samples
177 ((24), (25)). The results of quantification of these four miRNAs following forty cycles of PCR,
178 completed in less than 10 minutes with the xpress compared to 40 minutes using the LightCycler, are
179 presented in Figure 4. The relative abundances of the miRNAs detected by both systems were similar,
180 albeit with greater variation between technical replicates on the xpress. MiR-21 was the most
181 abundant (lowest Ct) and miR-22 the least abundant (highest Ct) miRNA for all samples on both
182 platforms. Significant differences between platforms in Ct values were observed for many miRNAs
183 amplified from the same sample (e.g. miR-126 in plasma sample 2, $p < 0.001$). This is likely due to the
184 combined effects of differences in the sample temperatures achieved during cycling, the detection
185 systems and performance of the individual assays under different conditions. Another class of small
186 RNA, a Y RNA fragment (hY4-3p) recently shown to be present in plasma (26), (27, 28) was detected
187 consistently by both platforms (Δ Ct between the two platforms across three plasma samples was 2.3
188 ± 0.3 SD) and could potentially provide a stable reference gene.

189 Faster PCR can be achieved by reducing hold times and although this can reduce sensitivity and
190 increase variability (29)), enzymes are now available from a range of manufacturers which perform
191 well in fast PCR. All data reported were generated with SYBR fast qPCR Mastermix (Kapa
192 Biosystems) but 18S rDNA failed to amplify using Quantitect (Qiagen) on the xpress, so users
193 should be aware that rigorous optimisation of different mastermixes is required for fast PCR. To
194 facilitate development of rapid assays incorporating fast PCR pre-processing steps must be minimised
195 and there is therefore a growing need to develop enzymes resistant to contaminants and inhibitors
196 present in a range of biological sample materials, such as soil, water and blood (30)).

197 Although many prototype rapid PCR systems have been reported with extremely fast ramp rates and
198 miniaturisation (5), (6), (31)) very few proceed to commercial release. Therefore the xpress rapid
199 thermal cycler, particularly given its standard block-based design, offers a unique opportunity for the
200 wider molecular research community to adopt fast PCR. The potential applications of fast PCR in
201 situations which require a rapid diagnosis (e.g. involvement of cardiac disease in dyspnoea (32)) or

202 chest pain) make this an exciting and rapidly expanding area of PCR development. If protocols can be
203 developed to enable reverse transcription and PCR directly from patient samples (30)), this platform
204 has the potential to make point-of care diagnostics based upon circulating microRNAs a reality.

205

206 **Author contributions**

207 WJA performed and analysed the experiments and assisted with manuscript preparation, EB and MD
208 performed experiments with plasma and assisted with manuscript preparation, REH provided plasma
209 samples and assisted with manuscript preparation, DAS conceived the study, analysed the data and
210 wrote the manuscript.

211

212 **Acknowledgements**

213 This work was supported by grants from the Department of Education and Learning (DEL), Invest
214 Northern Ireland (INI), the European Regional Development Fund and Fight For Sight.

215

216 **Competing Interests**

217 The authors declare no competing interests.

218

219 **References**

- 220 1. **Laurin, N., and C. Fréreau.** 2012. Optimization and validation of a fast amplification protocol
221 for AmpFISTR® Profiler Plus® for rapid forensic human identification. *Forensic Sci Int Genet*
222 *6:47–57.*
223
224 2. **Bahlmann, S., S. Hughes-Stamm, and D. Gangitano.** 2014. Development and evaluation of a
225 rapid PCR method for the PowerPlex®S5 system for forensic DNA profiling. *Leg Med (Tokyo)*
226 *16:227–233.*
227

- 228 3. **Wheeler, E.K., C.A. Hara, J. Frank, J. Deotte, S.B. Hall, W. Benett, C. Spadaccini, and N.R.**
229 **Beer.** 2011. Under-three minute PCR: probing the limits of fast amplification. *Analyst* 136:3707–
230 3712.
231
- 232 4. **Neuzil, P., C. Zhang, J. Pipper, S. Oh, and L. Zhuo.** 2006. Ultra fast miniaturized real-time
233 PCR: 40 cycles in less than six minutes. *Nucleic Acids Res.* 34:e77.
234
- 235 5. **Hashimoto, M., P.-C. Chen, M.W. Mitchell, D.E. Nikitopoulos, S.A. Soper, and M.C.**
236 **Murphy.** 2004. Rapid PCR in a continuous flow device. *Lab Chip* 4:638–645.
237
- 238 6. **Farrar, J.S., and C.T. Wittwer.** 2015. Extreme PCR: Efficient and Specific DNA Amplification
239 in 15-60 Seconds. *Clin. Chem.* 61:145–153.
240
- 241 7. **Wittwer, C.T., K.M. Ririe, R.V. Andrew, D.A. David, R.A. Gundry, and U.J. Balis.** 1997.
242 The LightCycler: a microvolume multisample fluorimeter with rapid temperature control.
243 *BioTechniques* 22:176–181.
244
- 245 8. **Mitchell, P.S., R.K. Parkin, E.M. Kroh, B.R. Fritz, S.K. Wyman, E.L. Pogosova-**
246 **Agadjanyan, A. Peterson, J. Noteboom, et al.** 2008. Circulating microRNAs as stable blood-
247 based markers for cancer detection. *Proc. Natl. Acad. Sci. U.S.A.* 105:10513–10518.
248
- 249 9. **Chen, X., Y. Ba, L. Ma, X. Cai, Y. Yin, K. Wang, J. Guo, Y. Zhang, et al.** 2008.
250 Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and
251 other diseases. *Cell Res.* 18:997–1006.
252
- 253 10. **Creemers, E.E., A.J. Tijssen, and Y.M. Pinto.** 2012. Circulating microRNAs: novel biomarkers
254 and extracellular communicators in cardiovascular disease? *Circ. Res.* 110:483–495.
255
- 256 11. **Weiland, M., X.-H. Gao, L. Zhou, and Q.-S. Mi.** 2012. Small RNAs have a large impact:
257 circulating microRNAs as biomarkers for human diseases. *RNA Biol* 9:850–859.
258
- 259 12. **Leidinger, P., C. Backes, S. Deutscher, K. Schmitt, S.C. Mueller, K. Frese, J. Haas, K.**
260 **Ruprecht, et al.** 2013. A blood based 12-miRNA signature of Alzheimer disease patients.
261 *Genome Biol.* 14:R78.
262
- 263 13. **Deddens, J.C., J.M. Colijn, M.I.F.J. Oerlemans, G. Pasterkamp, S.A. Chamuleau, P.A.**
264 **Doevendans, and J.P.G. Sluijter.** 2013. Circulating microRNAs as novel biomarkers for the
265 early diagnosis of acute coronary syndrome. *J Cardiovasc Transl Res* 6:884–898.
266
- 267 14. **Shi, R., and V.L. Chiang.** 2005. Facile means for quantifying microRNA expression by real-
268 time PCR. *BioTechniques* 39:519–525.
269
- 270 15. **Levesque-Sergerie, J.-P., M. Duquette, C. Thibault, L. Delbecchi, and N. Bissonnette.** 2007.
271 Detection limits of several commercial reverse transcriptase enzymes: impact on the low- and
272 high-abundance transcript levels assessed by quantitative RT-PCR. *BMC Mol. Biol.* 8:93.
273
- 274 16. **Selcuklu, S.D., M.T.A. Donoghue, and C. Spillane.** 2009. miR-21 as a key regulator of
275 oncogenic processes. *Biochem. Soc. Trans.* 37:918–925.
276
- 277 17. **Iorio, M.V., M. Ferracin, C.-G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, E. Magri, M.**
278 **Pedriali, et al.** 2005. MicroRNA Gene Expression Deregulation in Human Breast Cancer. *Cancer*
279 *Research* 65:7065–7070.
280
- 281 18. **Volinia, S., G.A. Calin, C.-G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, et**
282 **al.** 2006. A microRNA expression signature of human solid tumors defines cancer gene targets.

- 283 Proc. Natl. Acad. Sci. U.S.A. *103*:2257–2261.
284
- 285 19. **Thum, T., C. Gross, J. Fiedler, T. Fischer, S. Kissler, M. Bussen, P. Galuppo, S. Just, et al.**
286 2008. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in
287 fibroblasts. *Nature* *456*:980–984.
288
- 289 20. **Asaga, S., C. Kuo, T. Nguyen, M. Terpenning, A.E. Giuliano, and D.S.B. Hoon.** 2011. Direct
290 serum assay for microRNA-21 concentrations in early and advanced breast cancer. *Clin. Chem.*
291 *57*:84–91.
292
- 293 21. **Xu, J., C. Wu, X. Che, L. Wang, D. Yu, T. Zhang, L. Huang, H. Li, et al.** 2011. Circulating
294 MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or
295 chronic hepatitis. *Molecular Carcinogenesis* *50*:136–142.
296
- 297 22. **Zhang, J., Y. Yang, T. Yang, Y. Liu, A. Li, S. Fu, M. Wu, Z. Pan, and W. Zhou.** 2010.
298 microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis,
299 suppresses cell proliferation and tumourigenicity. *Br. J. Cancer* *103*:1215–1220.
300
- 301 23. **Wang, S., A.B. Aurora, B.A. Johnson, X. Qi, J. McAnally, J.A. Hill, J.A. Richardson, R.**
302 **Bassel-Duby, and E.N. Olson.** 2008. The endothelial-specific microRNA miR-126 governs
303 vascular integrity and angiogenesis. *Dev. Cell* *15*:261–271.
304
- 305 24. **Yu, L., N.W. Todd, L. Xing, Y. Xie, H. Zhang, Z. Liu, H. Fang, J. Zhang, et al.** 2010. Early
306 detection of lung adenocarcinoma in sputum by a panel of microRNA markers. *Int. J. Cancer*
307 *127*:2870–2878.
308
- 309 25. **Xing, L., N.W. Todd, L. Yu, H. Fang, and F. Jiang.** 2010. Early detection of squamous cell
310 lung cancer in sputum by a panel of microRNA markers. *Modern Pathology* *23*:1157–1164.
311
- 312 26. **Beatty, M., J. Guduric-Fuchs, E. Brown, S. Bridgett, U. Chakravarthy, R.E. Hogg, and D.A.**
313 **Simpson.** 2014. Small RNAs from plants, bacteria and fungi within the order Hypocreales are
314 ubiquitous in human plasma. *BMC Genomics* *15*:933.
315
- 316 27. **Dhahbi, J.M., S.R. Spindler, H. Atamna, D. Boffelli, P. Mote, and D.I.K. Martin.** 2013. 5'-
317 YRNA fragments derived by processing of transcripts from specific YRNA genes and
318 pseudogenes are abundant in human serum and plasma. *Physiol. Genomics* *45*:990–998.
319
- 320 28. **Dhahbi, J.M., S.R. Spindler, H. Atamna, D. Boffelli, and D.I. Martin.** 2014. Deep Sequencing
321 of Serum Small RNAs Identifies Patterns of 5' tRNA Half and YRNA Fragment Expression
322 Associated with Breast Cancer. *Biomark Cancer* *6*:37–47.
323
- 324 29. **Hilscher, C., W. Vahrson, and D.P. Dittmer.** 2005. Faster quantitative real-time PCR protocols
325 may lose sensitivity and show increased variability. *Nucleic Acids Res.* *33*:e182.
326
- 327 30. **Kermekchiev, M.B., L.I. Kirilova, E.E. Vail, and W.M. Barnes.** 2009. Mutants of Taq DNA
328 polymerase resistant to PCR inhibitors allow DNA amplification from whole blood and crude soil
329 samples. *Nucleic Acids Res.* *37*:e40.
330
- 331 31. **Salm, E., Y. Zhong, B. Reddy, C. Duarte-Guevara, V. Swaminathan, Y.-S. Liu, and R.**
332 **Bashir.** 2014. Electrical detection of nucleic acid amplification using an on-chip quasi-reference
333 electrode and a PVC REFET. *Anal. Chem.* *86*:6968–6975.
334
- 335 32. **Tijssen, A.J., E.E. Creemers, P.D. Moerland, L.J. de Windt, A.C. van der Wal, W.E. Kok,**
336 **and Y.M. Pinto.** 2010. MiR423-5p as a circulating biomarker for heart failure. *Circ. Res.*

337 106:1035–1039.

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

	Name	Sequence (5'-3')	T_M(°C)
RT oligos	miR-21	UAG CUU AUC AGA CUG AUG UUG AAA AAA AAA AAA A	52.4
	OligodT-RACE	GCG AGC ACA GAA TTA ATA CGA CTC ACT ATA GGT TTT TTT TTT TTV N	61.9
	Reverse RACE	GCG AGC ACA GAA TTA ATA CGA C	53.9
18 S	18 S Forward	AAA CGG CTA CCA CAT CCA AG	55.3
	18 S Reverse	CCT CCA ATG GAT CCT CGT TA	53.8
miRNAs	miR-10b-5p	TAC CCT GTA GAA CCG AAT TTG TG	54.7
	miR-468-5p	TCC TGT ACT GAG CTG CCC CGA	62.8
	miR-126-5p	CAT TAT TAC TTT TGG TAC GCG	49.6
	miR-22-3p	AAG CTG CCA GTT GAA GAA CTG T	57.1
	miR-21-5p	TAG CTT ATC AGA CTG ATG TTG A	50.9
Y-RNAs	Y-RNA-3p	CCC CCA CTG CTA AAT TTG ACT	55.2
	Y-RNA-5P	GGC TGG TCC GAT GGT AGT	56.8
Sequence and melting temperatures for oligonucleotides used in this investigation. Column 1 denotes the general class of oligonucleotides used and Column 2 the name of each, also providing information about target strand (5p or 3p for miRNAs). Column 3 provides sequence information (V denotes any nucleotide not T or U and N denotes any nucleotide). Column 4 T _M values were calculated by Integrated DNA Technologies.			

363 **Table 2. PCR cycling conditions.**

	xxpress			LightCycler480		
	Temp	Hold	Ramp rate	Temp	Hold	Ramp rate
	(°C)	(s)	(°C/s)	(°C)	(s)	(°C/s)
Initial Denaturation	95	20	10 (4.8 [†])	95	20	4.8
Denaturation	95	1	10 (4.8 [†])	95	1	4.8
Annealing	60	10	10 (2.5 [†])	60	10	2.5
Extension*						
Cooling	50	10	10 (2.5 [†])	50	10	2.5
<p>Cycling conditions for PCR. Ramp rates are shown for fast PCR and conventional PCR in parentheses. * Fluorescence was measured following each annealing and extension step. [†]Ramp rate used to assess consistency across the plate by amplification of 18S rDNA.</p>						

364

365

366

367

368

369

370

371

372

373

374 **Figure legends**

375 **Figure 1. The xpress system.** A) 96 well xxplate (bottom) compared to conventional 96 well and
376 384 well PCR plates (upper). (Scale bar represents 25 cm to allow a direct size comparison). B) The
377 xpress system comprises a heat sealer (left), centrifuge (center) and cycler unit (right).

378 **Figure 2. Variability in Ct values across plates on both systems.** A single 18S rDNA PCR
379 mastermix was distributed across 48 wells of both a Lightcycler 384 well plate and xpress 96 well
380 xxplate (5 µl reaction/well). PCR was performed with the same ramp rate on each thermal cycler (4.8
381 °C/s). Ct values are presented by row from well A1 (active wells are illustrated in Supplementary
382 Figure.1). Melt curve analysis was performed to confirm amplification of a single product (data not
383 shown).

384 **Figure 3. Standard curves generated by amplification of 18S rDNA from genomic DNA and**
385 **synthetic miR-21.** A) 18S rDNA standard curve analysis. Comparable dynamic range 0.1 pg- 10 ng
386 genomic DNA. Amplified using maximal ramp rate on each platform (n=3 technical replicates) (* p
387 <0.05, ** p<0.01). B) Synthetic miR-21 standard curve analysis. Comparable dynamic range 10⁹ - 10⁶
388 copies of template RNA. Amplified using maximal ramp rate on each platform (n=3 technical
389 replicates). For both datasets melt curve analysis confirmed the presence of a single product (data not
390 shown).

391 **Figure 4. Detection of microRNAs from human plasma samples by fast and standard PCR analysis.**
392 Cts for 4 microRNAs (miR-21, miR-22, miR-126, miR-486) and Y-RNA (Y-RNA-3p) on plasma
393 samples from 3 individuals (n=3 technical replicates). The relative levels of expression detected by
394 both systems were comparable. Gel and melt curve analysis was carried out to confirm amplification
395 of one product (data not shown).

396 **Supplementary Figure 1. Plate layout.** Reported data is presented by row starting from well A1.

397